SCHEMBL22979359

SCHEMBL22979359

O=c1[nH]c2c(Cl)cccc2c2nc(-c3ccncc3)nn12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.58
ROCK2 O75116 3/20 0.58
PIM1 P11309 3/20 0.58
GSK3B P49841 3/20 0.58
HIPK2 Q9H2X6 3/20 0.58
CLK4 Q9HAZ1 3/20 0.58
MAP4K4 O95819 2/20 0.58
DAPK3 O43293 2/20 0.58
GSK3A P49840 2/20 0.58
NEK4 P51957 2/20 0.58
CSNK2A1 P68400 2/20 0.58
ROCK1 Q13464 2/20 0.58
DYRK1A Q13627 2/20 0.58
PIM3 Q86V86 2/20 0.58
DYRK4 Q9NR20 2/20 0.58
MAPK13 O15264 1/20 0.58
MAPK12 P53778 1/20 0.58
PKN2 Q16513 1/20 0.58
SRPK1 Q96SB4 1/20 0.58
GABRP O00591 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22987595 0.87 XDH (0.58) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22987972 0.85 CDC7 (0.58) CDC7ROCK2PIM1GSK3BHIPK2
SCHEMBL22987905 0.84 KDM4E (0.69) DYRK1AGABRPGABRDGABRA1GABRB1
SCHEMBL22987906 0.82 XDH (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22987969 0.81 GABRP (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5909329 0.80 GABRP (0.82) CDC7ROCK2PIM1GSK3BHIPK2
SCHEMBL22988219 0.78 XDH (0.43) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22987631 0.78 XDH (0.43) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22987738 0.77 XDH (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22987726 0.77 XDH (0.58) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 CDC7 2350/4885ROCK2 1672/4885PIM1 3095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.